AstraZeneca
🇬🇧United Kingdom
- Country
- 🇬🇧United Kingdom
- Ownership
- Public
- Employees
- 89.9K
- Market Cap
- $270.3B
- Website
- http://www.astrazeneca.co.uk
- Introduction
AstraZeneca Plc is a holding company, which engages in the research, development, manufacture, and commercialization of prescription medicines. The company was founded on June 17, 1992 and is headquartered in Cambridge, the United Kingdom.
AZD0901 in Participants With Advanced Solid Tumours Expressing Claudin18.2
- First Posted Date
- 2024-01-23
- Last Posted Date
- 2024-10-04
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 123
- Registration Number
- NCT06219941
- Locations
- 🇬🇧
Research Site, Oxford, United Kingdom
Acalabrutinib Real World Italian obSErvational Study -ARISE
Recruiting
- Conditions
- First Posted Date
- 2024-01-16
- Last Posted Date
- 2024-11-11
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 190
- Registration Number
- NCT06205498
- Locations
- 🇮🇹
Research Site, Viterbo, Italy
Observational Secondary Data Study Describing Treatment With Dapagliflozin Among Adult Chronic Kidney Disease Patients
Recruiting
- Conditions
- First Posted Date
- 2024-01-12
- Last Posted Date
- 2024-08-13
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 1090
- Registration Number
- NCT06203704
- Locations
- 🇸🇮
Research Site, Zagorje, Slovenia
LTFU for All Cell and Gene Therapy Studies
Not yet recruiting
- Conditions
- Interventions
- First Posted Date
- 2024-01-08
- Last Posted Date
- 2024-07-05
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 64
- Registration Number
- NCT06194461
- Locations
- 🇦🇺
Research Site, East Melbourne, Australia
A Study to Investigate the Effect on QTcF of Baxdrostat Compared With Placebo, Using Moxifloxacin as a Positive Control, in Healthy Participants
Phase 1
Completed
- Conditions
- Interventions
- First Posted Date
- 2024-01-08
- Last Posted Date
- 2024-05-17
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 28
- Registration Number
- NCT06194032
- Locations
- 🇩🇪
Research Site, Berlin, Germany
EPIC-ATTR: A Study to Evaluate the Effect of Eplontersen on the Transthyretin Reduction and Long-term Safety in Chinese Subjects With Transthyretin Amyloid Cardiomyopathy
Phase 3
Recruiting
- Conditions
- Interventions
- First Posted Date
- 2024-01-08
- Last Posted Date
- 2024-07-17
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 60
- Registration Number
- NCT06194825
- Locations
- 🇨🇳
Research Site, Xi'an, China
To Evaluate the Efficacy/Safety of Osimertinib Prior to CRT and Maintenance of it With Stage III, Unresectable NSCLC With EGFR Mutations
Phase 2
Recruiting
- Conditions
- Interventions
- First Posted Date
- 2024-01-08
- Last Posted Date
- 2024-11-25
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 70
- Registration Number
- NCT06194448
- Locations
- 🇻🇳
Research Site, Ho Chi Minh, Vietnam
Study of Non-Small Cell Lung Cancer Patients in the US Receiving Standard-of-Care and Initiating an Approved Therapy With Risk of Pneumonitis/ILD
- First Posted Date
- 2024-01-05
- Last Posted Date
- 2024-10-29
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 600
- Registration Number
- NCT06192004
- Locations
- 🇺🇸
Research Site, Odessa, Texas, United States
UNFOLD Study Egypt
Recruiting
- Conditions
- First Posted Date
- 2024-01-03
- Last Posted Date
- 2024-12-03
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 400
- Registration Number
- NCT06188494
- Locations
- 🇪🇬
Research Site, Tanta, Egypt
A First-in-human Dose Escalation and Expansion Study to Evaluate the Safety, and Tolerability of AZD8421 Alone or in Combination in Participants With Selected Advanced or Metastatic Solid Tumors
Phase 1
Recruiting
- Conditions
- Interventions
- First Posted Date
- 2024-01-03
- Last Posted Date
- 2024-10-03
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 204
- Registration Number
- NCT06188520
- Locations
- 🇬🇧
Research Site, Manchester, United Kingdom
© Copyright 2024. All Rights Reserved by MedPath